Literature DB >> 25838266

High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.

Jessica L Halliley1, Surender Khurana2, Florian Krammer3, Theresa Fitzgerald4, Elizabeth M Coyle2, Ka Yan Chung2, Steven F Baker5, Hongmei Yang6, Luis Martínez-Sobrido5, John J Treanor4, Kanta Subbarao7, Hana Golding2, David J Topham1, Mark Y Sangster1.   

Abstract

Recent studies have shown that live attenuated influenza vaccines (LAIVs) expressing avian influenza virus hemagglutinins (HAs) prime for strong protective antibody responses to an inactivated influenza vaccine (IIV) containing the HA. To better understand this priming effect, we compared H7 HA head and stalk domain-specific B-cell responses in H7N7 LAIV-primed subjects and non-H7-primed controls after a single dose of H7N7 IIV. As previously reported, H7N7 LAIV-primed subjects but not control subjects generated strong hemagglutination-inhibiting and neutralizing antibody responses to the H7N7 IIV. Here, we found that the quantity, epitope diversity, and affinity of H7 head-specific antibodies increased rapidly in only H7N7 LAIV-primed subjects after receipt of the IIV. However, all cohorts generated a vigorous, high-affinity, stalk-specific antibody response. Consistent increases in circulating memory B-cell frequencies after receipt of the IIV reflected the specificity of high-affinity antibody production. Our findings emphasize the value of LAIVs as a vehicle for prepandemic vaccination.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Avian influenza; H7 hemagglutinin; anti-stalk antibodies; antibody affinity; live attenuated; memory B cells; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25838266      PMCID: PMC4577047          DOI: 10.1093/infdis/jiv210

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender.

Authors:  Surender Khurana; Nitin Verma; Kawsar R Talaat; Ruth A Karron; Hana Golding
Journal:  J Infect Dis       Date:  2011-12-29       Impact factor: 5.226

3.  Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination.

Authors:  Hye Mee Joo; Yuxia He; Aarthi Sundararajan; Lifang Huan; Mark Y Sangster
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

4.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

Authors:  Robert B Belshe; Sharon E Frey; Irene Graham; Mark J Mulligan; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry L Keyserling; Paul Spearman; Heather Hill; Mark Wolff
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

5.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

6.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 7.  Influenza vaccine immunology.

Authors:  Philip R Dormitzer; Grazia Galli; Flora Castellino; Hana Golding; Surender Khurana; Giuseppe Del Giudice; Rino Rappuoli
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

Authors:  Ruth A Karron; Kawsar Talaat; Catherine Luke; Karen Callahan; Bhagvanji Thumar; Susan Dilorenzo; Josephine McAuliffe; Elizabeth Schappell; Amorsolo Suguitan; Kimberly Mills; Grace Chen; Elaine Lamirande; Kathleen Coelingh; Hong Jin; Brian R Murphy; George Kemble; Kanta Subbarao
Journal:  Vaccine       Date:  2009-06-21       Impact factor: 3.641

9.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Authors:  Natalie Pica; Rong Hai; Florian Krammer; Taia T Wang; Jad Maamary; Dirk Eggink; Gene S Tan; Jens C Krause; Thomas Moran; Cheryl R Stein; David Banach; Jens Wrammert; Robert B Belshe; Adolfo García-Sastre; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

10.  A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

Authors:  Florian Krammer; Irina Margine; Gene S Tan; Natalie Pica; Jens C Krause; Peter Palese
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

View more
  27 in total

1.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Authors:  Wenqian He; Gene S Tan; Caitlin E Mullarkey; Amanda J Lee; Mannie Man Wai Lam; Florian Krammer; Carole Henry; Patrick C Wilson; Ali A Ashkar; Peter Palese; Matthew S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

Review 2.  Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Authors:  Daniel Stadlbauer; Raffael Nachbagauer; Philip Meade; Florian Krammer
Journal:  Front Med       Date:  2017-11-20       Impact factor: 4.592

3.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Authors:  Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

4.  Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.

Authors:  Jad Maamary; Taia T Wang; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

5.  Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Authors:  James Duehr; Teddy John Wohlbold; Lisa Oestereich; Veronika Chromikova; Fatima Amanat; Madhusudan Rajendran; Sergio Gomez-Medina; Ignacio Mena; Benjamin R tenOever; Adolfo García-Sastre; Christopher F Basler; Cesar Munoz-Fontela; Florian Krammer
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.

Authors:  Sinthujan Jegaskanda; Rosemarie D Mason; Sarah F Andrews; Adam K Wheatley; Ruijun Zhang; Glennys V Reynoso; David R Ambrozak; Celia P Santos; Catherine J Luke; Yumiko Matsuoka; Jason M Brenchley; Heather D Hickman; Kawsar R Talaat; Sallie R Permar; Hua-Xin Liao; Jonathan W Yewdell; Richard A Koup; Mario Roederer; Adrian B McDermott; Kanta Subbarao
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

7.  Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

Authors:  Hana M El Sahly; Robert L Atmar; Shital M Patel; Abbie Bellamy; Liwei Liu; Wenshan Hong; Huachen Zhu; Yi Guan; Wendy A Keitel
Journal:  Vaccine       Date:  2019-04-04       Impact factor: 3.641

Review 8.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

Review 9.  Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?

Authors:  Karlynn E Neu; Carole J Henry Dunand; Patrick C Wilson
Journal:  Curr Opin Immunol       Date:  2016-06-03       Impact factor: 7.486

10.  A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy.

Authors:  Andrew Cox; Stephen Dewhurst
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.